Omega-3 fatty acid (O3FA) levels and dimensional personality measures have been associated with major depression and the course of depressive illness. We sought to study the utility of O3FA levels and dimensional personality measures as predictors of early improvement with escitalopram.
Methods
Twenty-four participants were enrolled in an open-label trial of escitalopram 10 mg/d for 4 weeks. Baseline erythrocyte O3 levels and dimensional personality assessments were obtained.
Results
Using a conservative, intention-to-treat analysis, baseline neuroticism (r = -0.57; P = .007), as measured by the Revised NEO Personality Inventory but not erythrocyte O3 levels, was correlated with improvements on escitalopram. A facet analysis of the neuroticism domain showed the relationship with antidepressant response to be focused on trait anxiety (r = -0.65; P = .002).
Conclusions
Anxiety may have important prognostic implications on subsequent response to selective serotonin reuptake inhibitors, such as escitalopram.
HibbelnJR. Fish consumption and major depression. Lancet. 1998;351:1213.
2.
TanskanenAHibbelnJRTuomilehtoJ. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv. 2001;52:529–531.
3.
PeetMMurphyBShayJ. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998;43:315–319.
4.
MaesMChristopheADelangheJ. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275–291.
5.
SilversKMScottKM. Fish consumption and selfreported physical and mental health status. Public Health Nutr. 2002;5:427–431.
6.
AdamsPBLawsonSSanigorskiA. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996, 31(suppl):S157–S161.
7.
EdwardsRPeetMShayJ. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48:149.
8.
HakkarainenRPartonenTHaukkaJ. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry. 2004;161:567–569.
9.
PeetMHorrobinDF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry2002;59: 913–919
10.
NemetsBStahlZBelmakerRH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159:477–479.
11.
SuKPHuangSYChiuCC. Omega-3 fatty acids in major depressive disorder. A preliminary doubleblind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:267–271.
12.
JazayeriSTehrani-DoostMKeshavarzSA. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42:192–198.
13.
NemetsHNemetsBApterA. Omega-3 treatment of childhood depression: a controlled, doubleblind pilot study. Am J Psychiatry2006;163:1098–1100.
14.
GrenyerBFCroweTMeyerB. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1393–1396.
15.
MarangellLBMartinezJMZboyanHA. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160:996–998.
16.
SilversKMWoolleyCCHamiltonFC. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005;72:211–218.
17.
RogersPJAppletonKMKesslerD. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr.2008;99:421–431.
18.
FreemanMPHibbelnJRWisnerKL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67: 1954-1967.
19.
LinPYSuKP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68:1056–1061.
20.
AppletonKMHaywardRCGunnellD. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr. 2006;84:1308–1316.
21.
TanumLMaltUF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. Scand J Gastroenterol. 2000;35:935–941.
22.
BerlangaCHeinzeGTorresM. Personality and clinical predictors of recurrence of depression. Psychiatr Serv.1999;50:376–380.
23.
DavidsonJLipperSPeltonS. The response of depressed inpatients to isocarboxazid. J Clin Psycho-pharmacol. 1988;8:100–107.
24.
BoycePParkerG.Neuroticism as a predictor of outcome in depression. J Nerv Ment Dis. 1985;173:685–688.
25.
PetersenTPapakostasGIBottonariK. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002;109:9–16.
26.
JoycePRPaykelES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46:89–99.
27.
DuLBakishDRavindranAV. Does fluoxetine influence major depression by modifying five-factor personality traits? J Affect Disord. 2002;71:235–241.
28.
BagbyRMJoffeRTParkerJDA. Major depression and the five-factor model of personality. J Pers Disord. 1995;9:224–234.
29.
WeissmanMMPrusoffBAKlermanGL. Personality and the prediction of long-term outcome of depression. Am J Psychiatry. 1978;135:797–800.
30.
HirschfeldRMKlermanGLAndreasenNC. Psycho-social predictors of chronicity in depressed patients. Br J Psychiatry. 1986;148:648–654.
31.
QuiltyLC De Fruyt F, Rolland JP, . Dimensional personality traits and treatment outcome in patients with major depressive disorder. J Affect Disord 2008;108:241–250.
32.
CostaPTJr, BagbyRM, HerbstJH, . Personality self-reports are concurrently reliable and valid during acute depressive episodes. J Affect Disord. 2005;89:45–55.
33.
BagbyRMLevitanRDKennedySH. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry Res. 1999;86:211–216.
34.
QuiltyLCMeuselLABagbyRM. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord. 2008;111:67–73.
35.
KleindienstNEngelRRGreilW.Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med. 2005;35:1685–1694.
36.
CostaPTJr, McCraeRR.Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. J Pers Assess.1995;64:21–50.
MontgomerySAAsbergM.A new depression scale designed to be sensitive to change. Br J Psychiatry.1979;134:382–389.
39.
KobakKAWilliamsJBJeglicE. Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone. Depress Anxiety. 2008;25:913–919.
40.
HermensMLAdèrHJvan HoutHP, . Administering the MADRS by telephone or face-to-face: a validity study. Ann Gen Psychiatry. 2006;5:3.
41.
RoseHGOklanderM.Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res. 1965;6:428–431.
42.
SpectorAAAshbrookJDSantosEC. Quantitative analysis of uptake of free fatty acid by mammalian cells: lauric acid and human erythrocytes. J Lipid Res. 1972;13:445–451.
43.
MorrisonWRSmithLM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride–methanol. J Lipid Res.1964;5:600–608.
44.
MartinDDRobbinsMESpectorAA. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids. 1996;31:1283–1288.
45.
WilliardDEHarmonSDKaduceTL. Docosahexaenoic acid synthesis from n-3 polyunsaturated fatty acids in differentiated rat brain astrocytes. J Lipid Res. 2001;42:1368–1376.
46.
BlockRCHarrisWSReidKJ. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes?Am Heart J.2008;156: 1117–1123.
47.
WennbergMBergdahlIAStegmayrB. Fish intake, mercury, long-chain n-3 polyunsaturated fatty acids and risk of stroke in northern Sweden. Br J Nutr. 2007;98:1038–1045.
48.
BroadfieldECMcKeeverTMWhitehurstA. A case-control study of dietary and erythrocyte membrane fatty acids in asthma. Clin Exp Allergy2004;34:1232–1236.
49.
IsoHSatoSUmemuraU. Linoleic acid, other fatty acids, and the risk of stroke. Stroke. 2002;33:2086–2093.
50.
LevantBOziasMKDavisPF. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology. 2008;33:1279–1292.
51.
AkiskalHS. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psy-chiatr Scand Suppl. 1998;393:66–73.
52.
BruijnJAMolemanP van den Broek WW, . Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. J Psychiatr Res. 2001;35:331–337.
53.
FavaMRushAJAlpertJE. Difference in treatment outcome in outpatients with anxious versus non-anxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342–351.
54.
FavaMRushAJAlpertJE. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51:823–835.
55.
FrokjaerVGMortensenELNielsenFA. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry. 2008;63:569–576.
56.
TakanoAArakawaRHayashiM. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry. 2007;62:588–592.
57.
FiedorowiczJGMoserDJHynesSM. LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. Psychiatr Genet. 2007;17:3–4.
58.
GondaXRihmerZZsombokT. The 5HTTLPR polymorphism of the serotonin transporter gene is associated with affective temperaments as measured by TEMPS-A. J Affect Disord. 2006;91:125–131.
59.
SmeraldiEZanardiRBenedettiF. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508–511.
60.
PohlRYeraganiVKBalonR. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry. 1988;49:100–104.
61.
BurkeWJGergelIBoseA.Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331–336.
